ArticleScience advances2025
Upgraded circular single-stranded DNA regulators for multiple-input multiple-output gene circuits in mammalian cells.
Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- From Blueprint to Breakthrough: How Far Can We Fold DNA Origami for Nano-Enabled Technologies?JACS Au · 2026Review
- Long-stranded XNA-cssDNA hybrids for robust data storage.Science advances · 2026Article
- A low-toxicity circular single-stranded DNA platform for safe and potent IL-12 immunotherapy against hepatocellular carcinoma.Journal of nanobiotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synthetic gene networks hold promise for genetic diagnostics and gene therapy but face limitations due to insufficient molecular tools. Gene-encoded circular single-stranded DNA (Css DNA) has been developed as a switchable vector to enrich regulatory components beyond protein/RNA-based systems in mammalian cells. However, the previous Css DNA regulator suffered from constrained regulatory sequence flexibility, disability of multiple-input multiple-output (MIMO) signals, and lack of endogenous orthogonal regulation. Here, we address these challenges by engineering a "bridge" design into the Css DNA regulator. These bridges function as sequence-programmable switches to control gene expression, responding to endogenous molecular signals (such as ATP, APE1, and RNase H) and enabling trans-regulation within or between Css DNAs. We exploit the orthogonality of Css DNA regulator to construct the three-input three-output genetic circuits. The upgraded Css DNA-based regulatory strategy represents a versatile and powerful platform for gene regulation and provides a promising avenue for the development of synthetic gene networks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.